vorinostat has been researched along with Leukemia, Prolymphocytic, T-Cell in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Leukemia, Prolymphocytic, T-Cell: A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toutah, K | 1 |
| Nawar, N | 1 |
| Timonen, S | 1 |
| Sorger, H | 1 |
| Raouf, YS | 1 |
| Bukhari, S | 1 |
| von Jan, J | 1 |
| Ianevski, A | 1 |
| Gawel, JM | 1 |
| Olaoye, OO | 1 |
| Geletu, M | 1 |
| Abdeldayem, A | 1 |
| Israelian, J | 1 |
| Radu, TB | 1 |
| Sedighi, A | 1 |
| Bhatti, MN | 1 |
| Hassan, MM | 1 |
| Manaswiyoungkul, P | 1 |
| Shouksmith, AE | 1 |
| Neubauer, HA | 1 |
| de Araujo, ED | 1 |
| Aittokallio, T | 1 |
| Krämer, OH | 1 |
| Moriggl, R | 1 |
| Mustjoki, S | 1 |
| Herling, M | 1 |
| Gunning, PT | 1 |
1 other study available for vorinostat and Leukemia, Prolymphocytic, T-Cell
| Article | Year |
|---|---|
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, He | 2021 |